Literature DB >> 20708158

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.

Young Jun Koh1, Hak-Zoo Kim, Seong-Ik Hwang, Jeung Eun Lee, Nuri Oh, Keehoon Jung, Minah Kim, Kyung Eun Kim, Homin Kim, Nam-Kyu Lim, Choon-Ju Jeon, Gyun Min Lee, Byeong Hwa Jeon, Do-Hyun Nam, Hoon Ki Sung, Andras Nagy, Ook Joon Yoo, Gou Young Koh.   

Abstract

Two vascular growth factor families, VEGF and the angiopoietins, play critical and coordinate roles in tumor progression and metastasis. A single inhibitor targeting both VEGF and angiopoietins is not available. Here, we developed a chimeric decoy receptor, namely double anti-angiogenic protein (DAAP), which can simultaneously bind VEGF-A and angiopoietins, blocking their actions. Compared to VEGF-Trap or Tie2-Fc, which block either VEGF-A or angiopoietins alone, we believe DAAP is a highly effective molecule for regressing tumor angiogenesis and metastasis in implanted and spontaneous solid tumors; it can also effectively reduce ascites formation and vascular leakage in an ovarian carcinoma model. Thus, simultaneous blockade of VEGF-A and angiopoietins with DAAP is an effective therapeutic strategy for blocking tumor angiogenesis, metastasis, and vascular leakage. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708158     DOI: 10.1016/j.ccr.2010.07.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  69 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 2.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 3.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

Review 4.  Receptor tyrosine kinase-mediated angiogenesis.

Authors:  Michael Jeltsch; Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

5.  Lymphatic regulator PROX1 determines Schlemm's canal integrity and identity.

Authors:  Dae-Young Park; Junyeop Lee; Intae Park; Dongwon Choi; Sunju Lee; Sukhyun Song; Yoonha Hwang; Ki Yong Hong; Yoshikazu Nakaoka; Taija Makinen; Pilhan Kim; Kari Alitalo; Young-Kwon Hong; Gou Young Koh
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

6.  Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth.

Authors:  Guillaume Collet; Nathalie Lamerant-Fayel; Magdalena Tertil; Bouchra El Hafny-Rahbi; Jacek Stepniewski; Alan Guichard; Alexandra Foucault-Collet; Krzysztof Klimkiewicz; Stéphane Petoud; Agata Matejuk; Catherine Grillon; Alicja Jozkowicz; Jozef Dulak; Claudine Kieda
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

7.  A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

Authors:  G M Palmer; Z Tiran; Z Zhou; M E Capozzi; W Park; C Coletta; A Pyriochou; Y Kliger; O Levy; I Borukhov; M W Dewhirst; G Rotman; J S Penn; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

Authors:  Gabriela D'Amico; Emilia A Korhonen; Andrey Anisimov; Georgia Zarkada; Tanja Holopainen; René Hägerling; Friedemann Kiefer; Lauri Eklund; Raija Sormunen; Harri Elamaa; Rolf A Brekken; Ralf H Adams; Gou Young Koh; Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 9.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

10.  Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice.

Authors:  Hanseul Yang; Sungsu Lee; Seungjoo Lee; Kangsan Kim; Yeseul Yang; Jeong Hoon Kim; Ralf H Adams; James M Wells; Sean J Morrison; Gou Young Koh; Injune Kim
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.